CORRECTION article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1641733
Correction: Research progress of B7-H3 in malignant tumors
Provisionally accepted
- 1Liaoning University of Traditional Chinese Medicine, Shenyang, China
- 2Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Wrong affiliation, but not replacing with present addressThe Affiliation Sequence [1Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China,2The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China] was erroneously given as [1The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China,2Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China].The original version of this article has been updated.
Keywords: B7-H3(CD276), Malignant tumor, targeted therapy, Immunity, drug trials
Received: 05 Jun 2025; Accepted: 06 Jun 2025.
Copyright: © 2025 Zhao, Zhang and Shang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shuaixiang Zhao, Liaoning University of Traditional Chinese Medicine, Shenyang, China
Guanning Shang, Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.